- Home
- CCCC
CCCC
C4 Therapeutics Inc.
as 12-20-2024 4:00pm EST
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 396.0M | IPO Year: | 2020 |
| Target Price: | $10.67 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.61 - $11.88 | Next Earning Date: | 10-31-2024 |
| Revenue: | $33,668,000 | Revenue Growth: | 65.45% |
| Revenue Growth (this year): | 75.79% | Revenue Growth (next year): | -53.55% |
Latest C4 Therapeutics Inc. News
CCCC Breaking Stock News: Dive into CCCC Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Wells Fargo Upgrades C4 Therapeutics to Overweight From Equalweight, Raises Price Target to $12 From $8
GlobeNewswire
14 days ago
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
GlobeNewswire
a month ago
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
GlobeNewswire
2 months ago
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
GlobeNewswire
2 months ago
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
Simply Wall St.
2 months ago
C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
2 months ago
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
2 months ago
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Compare CCCC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CCCC C4 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.